Molecular diagnosis of autosomal dominant polycystic kidney disease using next-generation sequencing.

TitleMolecular diagnosis of autosomal dominant polycystic kidney disease using next-generation sequencing.
Publication TypeJournal Article
Year of Publication2014
AuthorsTan AY, Michaeel A, Liu G, Elemento O, Blumenfeld J, Donahue S, Parker T, Levine D, Rennert H
JournalJ Mol Diagn
Volume16
Issue2
Pagination216-28
Date Published2014 Mar
ISSN1943-7811
KeywordsDNA Mutational Analysis, Exons, Gene Order, Genetic Testing, High-Throughput Nucleotide Sequencing, Humans, Mutation, Polycystic Kidney, Autosomal Dominant, Polymerase Chain Reaction, Prospective Studies, Registries, Sensitivity and Specificity, TRPP Cation Channels
Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations in PKD1 and PKD2. However, genetic analysis is complicated by six PKD1 pseudogenes, large gene sizes, and allelic heterogeneity. We developed a new clinical assay for PKD gene analysis using paired-end next-generation sequencing (NGS) by multiplexing individually bar-coded long-range PCR libraries and analyzing them in one Illumina MiSeq flow cell. The data analysis pipeline has been optimized and automated with Unix shell scripts to accommodate variant calls. This approach was validated using a cohort of 25 patients with ADPKD previously analyzed by Sanger sequencing. A total of 250 genetic variants were identified by NGS, spanning the entire exonic and adjacent intronic regions of PKD1 and PKD2, including all 16 pathogenic mutations. In addition, we identified three novel mutations in a mutation-negative cohort of 24 patients with ADPKD previously analyzed by Sanger sequencing. This NGS method achieved sensitivity of 99.2% (95% CI, 96.8%-99.9%) and specificity of 99.9% (95% CI, 99.7%-100.0%), with cost and turnaround time reduced by as much as 70%. Prospective NGS analysis of 25 patients with ADPKD demonstrated a detection rate comparable with Sanger standards. In conclusion, the NGS method was superior to Sanger sequencing for detecting PKD gene mutations, achieving high sensitivity and improved gene coverage. These characteristics suggest that NGS would be an appropriate new standard for clinical genetic testing of ADPKD.

DOI10.1016/j.jmoldx.2013.10.005
Alternate JournalJ Mol Diagn
PubMed ID24374109
PubMed Central IDPMC3937536
Grant ListUL1 RR024143-01 / RR / NCRR NIH HHS / United States
Related Lab: 
Related Faculty: 
Hanna Rennert, Ph.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700